MX9803271A - Uso de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,6-tetrahid ropiridina para la preparacion de farmacos para el tratamiento de esclerosis lateral aminotrofica. - Google Patents

Uso de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,6-tetrahid ropiridina para la preparacion de farmacos para el tratamiento de esclerosis lateral aminotrofica.

Info

Publication number
MX9803271A
MX9803271A MX9803271A MX9803271A MX9803271A MX 9803271 A MX9803271 A MX 9803271A MX 9803271 A MX9803271 A MX 9803271A MX 9803271 A MX9803271 A MX 9803271A MX 9803271 A MX9803271 A MX 9803271A
Authority
MX
Mexico
Prior art keywords
etrahydropyridine
ylethyl
naphth
trifluoromethylphenyl
lateral sclerosis
Prior art date
Application number
MX9803271A
Other languages
English (en)
Other versions
MXPA98003271A (es
Inventor
Patrice Douillet
Jacqueline Fournier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512635A external-priority patent/FR2740343B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX9803271A publication Critical patent/MX9803271A/es
Publication of MXPA98003271A publication Critical patent/MXPA98003271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion se refiere a la utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2, 3,6-tetrahidropiridona o una de sus sales de adicion con los ácidos farmacéuticamente aceptables, para la preparacion de fármacos para el tratamiento de la esclerosis lateral amiotrofica (ALS).
MXPA/A/1998/003271A 1995-10-26 1998-04-24 Uso de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1, 2, 3, 6-tetrahidropiridina para la preparacion de farmacos para el tratamiento de esclerosis lateral amiotrofica MXPA98003271A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR96/07336 1996-06-13
FR9607336 1996-06-13
FR95/12635 1996-06-13

Publications (2)

Publication Number Publication Date
MX9803271A true MX9803271A (es) 1998-09-30
MXPA98003271A MXPA98003271A (es) 1998-11-16

Family

ID=

Also Published As

Publication number Publication date
PT866704E (pt) 2001-07-31
DE69612510T2 (de) 2001-11-22
EP0866704A1 (fr) 1998-09-30
CZ293360B6 (cs) 2004-04-14
KR100472793B1 (ko) 2005-06-16
HK1016904A1 (en) 1999-11-12
DK0866704T3 (da) 2001-07-16
AU7308496A (en) 1997-05-15
UA57004C2 (uk) 2003-06-16
CZ129698A3 (cs) 1998-07-15
CN1202826A (zh) 1998-12-23
AU719342B2 (en) 2000-05-04
HUP9802945A3 (en) 1999-05-28
NO981856D0 (no) 1998-04-24
JP3468526B2 (ja) 2003-11-17
TR199800717T2 (xx) 1998-09-21
IL124091A (en) 2003-10-31
SI0866704T1 (en) 2001-08-31
ATE200423T1 (de) 2001-04-15
EP0866704B1 (fr) 2001-04-11
EE04177B1 (et) 2003-12-15
NO981856L (no) 1998-06-11
DE69612510D1 (de) 2001-05-17
SK52698A3 (en) 1998-09-09
KR19990067057A (ko) 1999-08-16
NZ320355A (en) 2000-03-27
US6043251A (en) 2000-03-28
CA2235747A1 (en) 1997-05-01
CA2235747C (en) 2006-01-03
SK284099B6 (sk) 2004-09-08
NO316256B1 (no) 2004-01-05
WO1997015304A1 (fr) 1997-05-01
JPH11515012A (ja) 1999-12-21
IS1961B (is) 2004-11-15
ES2159362T3 (es) 2001-10-01
IS4722A (is) 1998-04-21
BR9611124A (pt) 1999-05-11
GR3036027T3 (en) 2001-09-28
CN1104241C (zh) 2003-04-02
CY2279B1 (en) 2003-07-04
HU222039B1 (hu) 2003-03-28
HUP9802945A2 (hu) 1999-04-28
EE9800132A (et) 1998-10-15

Similar Documents

Publication Publication Date Title
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
MY108885A (en) Heterocyclic-cyclic amine derivatives.
MY112915A (en) Multiple unit tableted dosage form 1
NZ333588A (en) Sulphamates as anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
UA41909C2 (uk) Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
UA41355C2 (uk) Засіб для лікування нейро-сніду
CA2235747A1 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
UA35584C2 (uk) Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
ES2108595A1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
AU9139791A (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
HK1015283A1 (en) Montirelin for inhibiting sleep apnea
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
PH31258A (en) New use of ropivacaine.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
IL126795A0 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.